Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

被引：4

作者：

Bagot, Martine ^{[1
]}

Kim, Youn H. ^{[2
]}

Ortiz-Romero, Pablo L. ^{[3
]}

Zinzani, Pier Luigi ^{[4
]}

Mehta-Shah, Neha ^{[5
]}

Dereure, Olivier ^{[6
]}

Beylot-Barry, Marie ^{[7
]}

Dalle, Stephane ^{[8
]}

Jacobsen, Eric D. ^{[9
]}

Huen, Auris ^{[10
]}

Combalia, Andrea ^{[11
]}

Battistella, Maxime ^{[12
]}

Gru, Alejandro A. ^{[13
]}

Moins-Teisserenc, Helene ^{[14
]}

Khodadoust, Michael S. ^{[15
,16
]}

Viotti, Julien ^{[17
]}

Paiva, Christine ^{[17
]}

Muller, Marianna ^{[17
]}

Porcu, Pierluigi ^{[18
]}

机构：

[1] Univ Paris Cite, Hop St Louis, Inserm U976, Dept Dermatol, Paris, France

[2] Stanford Canc Inst, Stanford, CA USA

[3] Univ Complutense, Hosp Octubre 12, Med Sch, Dept Dermatol, Madrid, Spain

[4] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[5] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA

[6] Univ Montpellier I, CHU Montpellier, Dept Dermatol, Montpellier, France

[7] CHU Bordeaux, Hop St Andre, Dept Dermatol, Bordeaux, France

[8] Hosp Civils Lyon, Dept Dermatol, Lyon, France

[9] Dana Farber Canc Inst, Boston, MA 02115 USA

[10] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA

[11] Hosp Clin Barcelona, Dept Dermatol, Barcelona, Spain

[12] Univ Paris 07, Hop St Louis, AP HP, INSERM U1165, Paris, France

[13] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA

[14] Univ Paris Cite, Hop St Louis, AP HP, Hematol Lab,INSERM U976, Paris, France

[15] Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA

[16] Stanford Univ, Dept Med, Div Hematol, Stanford, CA 94305 USA

[17] INNATE PHARMA, Marseille, France

[18] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr Jefferson Hlth, Philadelphia, PA 19107 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-160239

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3760 / 3761

页数：2

共 50 条

[1] Lacutamab in Patients with Relapsed and Refractory Sezary Syndrome: Results from the Tellomak Phase 2 Trial
Bagot, Martine
Kim, Youn H.
Geskin, Larisa J.
Ortiz-Romero, Pablo L.
Kim, Ellen
Mehta-Shah, Neha
Dereure, Olivier
Oro, Saskia
Beylot-Barry, Marie
Dalle, Stephane
Jacobsen, Eric
Lansigan, Frederick
Ram-Wolff, Caroline
Khodadoust, Michael S.
Battistella, Maxime
Gru, Alejandro A.
Moins-Teisserenc, Helene
Zinzani, Pier Luigi
Viotti, Julien
Paiva, Christine
Muller, Marianna
Porcu, Pierluigi
BLOOD, 2023, 142
[2] Lacutamab in Patients with Relapsed and Refractory Se′zary Syndrome: Results from the TELLOMAK Phase 2 Trial
Bagot, M.
Kim, Y. -H.
Geskin, L. J.
Ortiz-Romero, P. L.
Kim, E.
Mehta-Shah, N.
Dereure, O.
Oro, S.
Beylot-Barry, M.
Dalle, S.
Jacobsen, E.
Lansigan, F.
Ram-Wolff, C.
Khodadoust, M.
Battistella, M.
Gru, A.
Moins-Teisserenc, H.
Zinzani, P. L.
Viotti, J.
Paiva, C.
Boyer-Chammard, A.
Porcu, P.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S26 - S26
[3] Lacutamab in patients with relapsed and/or refractory mycosis fungoides: results from the TELLOMAK phase 2 trial
Porcu, P.
Bagot, M.
Ram-Wolff, C.
Huen, A. O.
Dalle, S.
Poligone, B.
Mehta-Shah, N.
Duval-Modeste, A. -B.
Zinzani, P. L.
Woei-A-Jin, S.
Eigentler, T.
Combalia, A.
Sokol, L.
Battistella, M.
Gru, A.
Moins-Teisserenc, H.
Viotti, J.
Paiva, C.
Boyer-Chammard, A.
Kim, Y. -H.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S26 - S27
[4] Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Results from the TELLOMAK phase 2 trial.
Porcu, Pierluigi
Bagot, Martine
Ram-Wolff, Caroline
Kim, Youn H.
Huen, Auris
Dalle, Stephane
Poligone, Brian
Mehta-Shah, Neha
Modeste, Anne Benedicte Duval
Zinzani, Pier Luigi
Woei-A-Jin, Feng Jung Sherida Harriette
Eigentler, Thomas
Combalia, Andrea
Sokol, Lubomir
Battistella, Maxime
Gru, Alejandro
Teisserenc, Helene Moins
Viotti, Julien
Paiva, Christine
Chammard, Agnes Boyer
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Lacutamab in patients with advanced mycosis fungoides according to KIR3DL2 expression: stage 1 results from the TELLOMAK phase 2 trial
Bagot, M.
Muller, M.
Kim, Y. H.
Ortiz-Romero, P. L.
Zinzani, P. L.
Beylot-Barry, M.
Dalle, S.
Jacobsen, E.
Combalia, A.
Huen, A.
Mehta-Shah, N.
Khodadoust, M. S.
Viotti, J.
Paiva, C.
Porcu, P.
EUROPEAN JOURNAL OF CANCER, 2022, 173 : S20 - S21
[6] Lacutamab in patients (pts) with advanced mycosis fungoides (MF) according to KIR3DL2 expression: early results from the TELLOMAK phase 2 trial
Bagot, Martine
Kim, Youn
Zinzani, Pier Luigi
Dalle, Stephane
Beylot-Barry, Marie
Ortiz-Romero, Pablo L.
Cambalia, Andrea
Dereure, Olivier
Mortier, Laurent
Jacobsen, Eric
Battistella, Maxime
Gru, Alejandro
Moins-Teisserenc, Helene
Paiva, Christine
Boyer-Chammard, Agnes
Rotolo, Federico
Azim, Hatem A.
Porcu, Pierluigi
EUROPEAN JOURNAL OF CANCER, 2021, 156 : S20 - S21
[7] Interim analysis results from a phase II trial of bupropion for Methamphetamine dependence
Elkashef, A
Rawson, R
Smith, E
Pearce, V
Campbell, J
Carlton, B
Gorodetzky, C
Haning, W
Mawhinney, J
McCann, M
Pham, T
Weis, D
Ling, W
Vocci, F
JOURNAL OF ADDICTIVE DISEASES, 2005, 24 (02) : 120 - 120
[8] Fludarabine phosphate in advanced mycosis fungoides Sezary syndrome: A phase II trial.
Bernengo, MG
Fierro, MT
Quaglino, P
Verrone, A
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1997, 109 (03) : 490 - 490
[9] Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Results of an Interim Analysis
Brammer, Jonathan E.
Zinzani, Pier Luigi
Zain, Jasmine
Mead, Monica
Casulo, Carla
Jacobsen, Eric D.
Gritti, Giuseppe
Litwak, Debra
Cohan, David
Katz, Danica J.
Mehta-Shah, Neha
Pro, Barbara
Horwitz, Steven M.
BLOOD, 2021, 138
[10] Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma
Zakharia, Yousef
McWilliams, Robert
Shaheen, Monaster
Grossman, Kenneth
Drabick, Joseph
Milhem, Mohammed
Rixie, Olivier
Khleif, Samir
Lott, Ryan
Kennedy, Eugene
Munn, David
Vahanian, Nicholas
Link, Charles
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →